E Fund Management Co., Ltd. Replimune Group, Inc. Transaction History

E Fund Management Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$6.87 - $9.31 $38,492 - $52,163	5,603 Added 22.65%	30,342 $247,000
Q4 2023 Feb 06, 2024	BUY	$6.75 - $16.18 $166,988 - $400,277	24,739 New	24,739 $208,000
Q1 2023 May 11, 2023	BUY	$17.48 - $29.09 $215,091 - $357,952	12,305 New	12,305 $217,000
Q1 2021 May 12, 2021	BUY	$30.22 - $45.57 $123,267 - $185,880	4,079 New	4,079 $124,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.